Literature DB >> 9597248

Problems with antimicrobial resistance in gram-positive cocci.

R C Moellering1.   

Abstract

The development of antimicrobial resistance has almost invariably accompanied the therapeutic use of antimicrobial agents. Newer antimicrobials have succeeded partly but not entirely in overcoming the problem of resistance. Antimicrobial resistance in gram-positive cocci has achieved its greatest prominence in the past 15 years. There has been a steady erosion of antimicrobial activity against gram-positive cocci. The presentations in this symposium dealt with some of the important problems of antimicrobial resistance in gram-positive cocci, including methicillin resistance and multidrug resistance in staphylococci, penicillin resistance in pneumococci, and vancomycin resistance in enterococci. A related problem that warrants attention is the potential for explosive development of macrolide resistance in gram-positive cocci. This potential is particularly pertinent because the popularity of a number of new macrolides has led to a striking increase in their use. This occurrence will almost certainly be accompanied by a generalized increase in resistance in gram-positive cocci.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597248     DOI: 10.1086/520288

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.

Authors:  H W Boucher; C Thauvin-Eliopoulos; D Loebenberg; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Role of global surveillance in combating bacterial resistance.

Authors:  A Marchese; G C Schito
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Molecular properties of bacterial multidrug transporters.

Authors:  M Putman; H W van Veen; W N Konings
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

4.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

5.  In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection.

Authors:  C Silvestri; O Cirioni; D Arzeni; R Ghiselli; O Simonetti; F Orlando; G Ganzetti; S Staffolani; L Brescini; M Provinciali; A Offidani; M Guerrieri; A Giacometti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-11       Impact factor: 3.267

6.  Structure of the multidrug resistance efflux transporter EmrE from Escherichia coli.

Authors:  Che Ma; Geoffrey Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

7.  Nasal carriage of methicillin-resistant staphylococcus aureus among ICU personnel working at Zahedan University, southeastern Iran.

Authors:  Batool Sharifi-Mood; Maliheh Metanat; Roya Alavi-Naini; Asadollah Shakeri; Zakaria Bameri; Maryam Imani
Journal:  Caspian J Intern Med       Date:  2013

8.  Nasal carriage of multi-drug resistant Staphylococcus aureus in healthy inhabitants of Amassoma in Niger delta region of Nigeria.

Authors:  A Onanuga; T C Temedie
Journal:  Afr Health Sci       Date:  2011-06       Impact factor: 0.927

9.  Determinants of acquisition and carriage of Staphylococcus aureus in infancy.

Authors:  Sharon J Peacock; Anita Justice; D Griffiths; G D I de Silva; M N Kantzanou; Derrick Crook; Karen Sleeman; Nicholas P J Day
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

10.  Positive nasal culture of methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for surgical site infection in orthopedics.

Authors:  Koichi Yano; Yukihide Minoda; Akira Sakawa; Yoshihiro Kuwano; Kyoko Kondo; Wakaba Fukushima; Koichi Tada
Journal:  Acta Orthop       Date:  2009-08       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.